Dr. Michael Alonso is a Scientific Co-Founder, and Vice President of Immunology & Pharmacology at Bolt Biotherapeutics, a biotechnology company developing immunotherapies that activate myeloid cells. He discusses targeting tumors by covering them in “eat me” signals, considerations for moving drugs into the clinic, and building teams in biotech.
Read More
Dr. Alice Long is an Associate Member of the Center for Translational Immunology at Benaroya Research Institute at Virginia Mason. The Long lab is focused on understanding how tolerance is lost in autoimmunity, specifically as it related to type 1 diabetes. Dr. Long discusses the work she presented at the American Association of Immunologists’ annual meeting, IMMUNOLOGY2022, on CD8 T cell exhaustion and Treg modulation.
Read More
Dr. Shruti Naik is an Assistant Professor of Biological Sciences at New York University Langone Medical Center. She studies immunity in the epithelial tissues that line our body to understand how environmental stimuli collaborate with genetic factors to influence health and drive disease at these interfaces. She discusses the work she’s presenting at the American Association of Immunologists’ annual meeting, IMMUNOLOGY2022, on trained immunity and immune-epithelial crosstalk in tissue repair.
Read More
Dr. Gwendalyn Randolph is the Emil R. Unanue Distinguished Professor in the Department of Immunology and Pathology at Washington University in St. Louis. Research in her lab integrates the study of monocytes, monocyte-derived cells, and dendritic cells with vascular and lymphatic vessel biology. She discusses the work she’s presenting at the American Association of Immunologists’ annual meeting, IMMUNOLOGY2022, on the diversity, function, and mysteries of peritoneal macrophages. 
Read More
Dr. Michael Rosenblum is a Professor of Dermatology at the University of California, San Francisco. His lab seeks to to understand how immune responses are regulated in tissues and how this knowledge can be exploited for therapeutic benefit. They are currently investigating how Tregs control immune responses in tissues, as well as their “alternative” functions. He talks about early-life inflammation and type 2 helper T cells in the skin, and how Tregs can be manipulated to target autoimmune diseases and cancer.
Read More